SynthesisAnnals of surgical oncology2026
Reassessing the Role of Hepatopancreatoduodenectomy in Advanced Biliary Tract Cancer: A Systematic Review and Single-Arm Meta-Analysis of Modern Case Series.
Synthesis in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ASO Author Reflections: Hepatopancreatoduodenectomy in Biliary Tract Cancer-Where We Stand and What Lies Ahead.Annals of surgical oncology · 2026Article
- Present and future of liver transplantation for cholangiocellular carcinoma: moving toward personalized multiparametric transplantability patterns.Transplant international : official journal of the European Society for Organ Transplantation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to assess perioperative safety and long-term survival after hepatopancreatoduodenectomy (HPD) by performing a systematic review and single-arm meta-analysis of studies published since 2005. The HPD procedure is a high-risk but potentially curative treatment for advanced bile duct and gallbladder cancers. Although perioperative outcomes have improved over time, an updated synthesis of contemporary evidence remains limited.
methodsThe PubMed, Embase, and Web of Science databases were systematically searched to identify studies published between January 2005 and March 2025. Eligible studies reported outcomes of HPD for bile duct or gallbladder cancers. Pooled estimates for morbidity, 90 day mortality, R0 resection, and 5 year overall survival (OS) rates were calculated using random- or common-effects models. Risk of bias was assessed using the ROBINS-I tool.
resultsThis meta-analysis included 18 studies involving 707 patients. The pooled morbidity rate was 0.64 (95% confidence interval [CI, 0.53-0.74), and the 90 day mortality rate was 0.10 (95% CI, 0.05-0.20). The R0 resection rate was 0.79 (95% CI, 0.76-0.82), and the 5 year OS was 0.32 (95% CI, 0.28-0.37). Subgroup analyses showed better perioperative outcomes for gallbladder cancer but superior long-term survival for bile duct cancer.
conclusionsThe HPD procedure offers an acceptable perioperative risk and favorable long-term survival for selected patients, particularly those with bile duct cancer. In contrast, the lack of long-term survival benefit of HPD for gallbladder cancer supports the prevailing view that HPD should not be routinely recommended for this indication. These findings provide contemporary benchmarks and may inform refinement of surgical indication criteria for HPD.
Indexed as
Identifiers
41212458What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.